Business Wire

Historic Partnership between the Weizmann Institute of Science and Institut Curie

25.3.2019 19:54:00 EET | Business Wire | Press release

Share

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.

Collaborative research programs

This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot. Each research program will be organized around a pair of researchers with a scientist from Institut Curie and a scientist from the Weizmann Institute of Sciences, who will receive support on the annual basis. This partnership also includes exchanges of scientists and a Curie-Weizmann symposium organized every two years, with alternate locations in Rehovot, Israel, and in Paris, which will be focused on one of the subjects of research cooperation.
To finance the start of this cooperation, Institut Curie and the Weizmann Institute of Sciences will finance this research program for €200,000 each, and will organize a joint fundraiser with philanthropists and corporate sponsors.

Projects with high hopes
There are numerous common interests between the two Institutes. They can range from the description of defects in cell nuclei to the mechanics of cell migration, or the behavior of neural networks. A few examples of exciting ongoing projects are highlighted below.
During his sabbatical visit at Institut Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in several projects ranging from cell migration to collective cell behaviors and neuron growth. For instance, he developed a theory in collaboration with Raphael Voituriez (Sorbonne University), which explains the observations of the team of Matthieu Piel (Institut Curie) on the links between persistence and speed of migrating cells. This theory gave rise to collaborative developments between these three teams to predict important aspects of the migratory behavior of immune cells.
He also collaborated with Pascal Silberzan at Institut Curie to understand the behavior of cells packed at very high density on a surface. This joint work combining experiments and theory, has highlighted the importance of an intrinsic biological ageing of the cell population. This project has helped understanding how cells can come to an arrest while maintaining a capacity to respond to external perturbations such as an injury.
Elisha Moses (Weizmann Institute) has a longstanding interaction with the group of Professor Jean-Louis Viovy (Institut Curie), now headed by Stéphanie Descroix, on the applications of microfluidic devices to the study of living neuronal networks. He spent three months in Paris, during which he and Dr. Catherine Villard of the Descroix lab developed an optogenetic assay for guiding axonal growth. This work has the potential for controlling growth of neurons and of neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two talented researchers who were working on the project as students, have now graduated and branched off into very interesting conceptual and practical applications of this approach.

An important complementarity
The two institutions are both highly complementary and display many mutually common attributes.
Institut Curie is the premier research center in France conducting cancer research, including all facets of carcinogenesis. Its research center brings together 1,200 researchers working in 12 joint research units organized in four areas based on natural scientific interactions and robust medical potentiality. A strong advocate of international cooperation , it welcomes more than 80 nationalities. Equipped with advanced technology platforms, it is an important resource for researchers around the world. Institut Curie is also a state-of-the-art hospital complex that provides care and support for all cancer types and welcomes more than 50,000 patients each year. It has developed particularly innovative treatments directly from the work of its research center. Institut Curie also trains students in science and cancer research with the goal of increasing the knowledge about the topic.
The Weizmann Institute of Science is among the ten premier institutes of fundamental research in the world: 2,500 scientists work on its campus in Rehovot in the complementary fields of mathematics and computer science, physics, biology, chemistry, and biochemistry. The Weizmann Institute of Science has a long history of research and discoveries rooted in a mission of advancement of science for the benefit of humanity; cancer research accounts for 40% of the total budget of the Institute, which shapes and hosts a large part of the leadership in Israel and contributes to the advancement and understanding of scientific issues among all audiences.
Both institutions have powerful means of technology transfer that leverage the discoveries of their labs for the benefit of patients, whether through the creation of medications, medical devices or other technologies.

A shared vision of science
Science at the service of people - this is the best way to describe the credo of the two institutes, both of which were founded upon great personalities who have made an important mark in the history of the world.
Chaim Weizmann, chemist and author of many discoveries and publications, is the founder of the Weizmann Institute, and was the first president of the State of Israel between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the Radium Institute in 1909. The first female professor and holder of a chair position at the Sorbonne, the first woman to win two Nobel prizes and be enshrined at the Pantheon in Paris on her own merit. In many ways, these two scientists have had a remarkable journey.
But beyond these prestigious founders, the two institutes share the same vision of science, at the service of people and driven by strong values, the same curiosity for discovery and knowledge at the service of human health.
The Weizmann Institute of Science and Institut Curie also share a common belief that international collaborations in the field of institut-curie.org science and the exchange of ideas across interdisciplinary boundaries can accelerate progress to the benefit of humanity.
It is this common ground which today enables this collaboration to take root and which will tomorrow allow us to multiply efforts and as a result enjoy major new discoveries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yohan Philippe
yohan.philippe@curie.fr
+33 (0)1 56 24 55 53

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye